Literature DB >> 28807443

Acute massıve pulmonary embolism assocıated wıth olanzapıne.

Emine Keles1, Sevinc Sarinc Ulasli2, Nursel Calik Basaran3, Elif Babaoglu2, Deniz Koksal2.   

Abstract

Treatment with low-potency anti-psychotic agents is an important risk factor in the development of pulmonary embolism (PE). We report a case of 74years old female patient receiving olanzapine for psychotic depression admitted to the emergency service with the complaints of chest pain and shortness of breath. She had tachypnea, hypotension and tachycardia. Arterial blood gas analysis showed hypoxemia-hypocapnia and D-dimer level was high. Computed tomographic pulmonary angiography (CTPA) demonstrated pulmonary embolism in both main pulmonary arteries, through lobar and segmental branches. Tissue plasminogen activator (t-PA) was administered in intensive care unit. As the only possible risk factor for PE was olanzapine, olanzapine treatment was terminated with pyschiatry consultation. During the 12-month follow-up of the patient; malignancy was not observed. Diagnosis and prevention of PE are the important goals to reduce morbidity and mortality in subjects receiving olanzapine.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Olanzapine; Pulmonary embolism; Thrombolytic treatment

Mesh:

Substances:

Year:  2017        PMID: 28807443     DOI: 10.1016/j.ajem.2017.07.026

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  2 in total

1.  Is there association of olanzapine and pulmonary embolism: A case report.

Authors:  Lumin Wang; Yijiao Xu; Weiwen Jiang; Jiaxin Liu; Chang Cao; Yun Shen; Xiong Xiao; Yanrong Ye
Journal:  Clin Case Rep       Date:  2022-06-03

2.  What are the incidence and risk factors of in-hospital mortality after venous thromboembolism events in total hip and knee arthroplasty patients?

Authors:  Alisina Shahi; Thomas L Bradbury; George N Guild; Usama Hassan Saleh; Elie Ghanem; Ali Oliashirazi
Journal:  Arthroplast Today       Date:  2018-05-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.